BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 11739153)

  • 1. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment.
    Giuliani N; Bataille R; Mancini C; Lazzaretti M; Barillé S
    Blood; 2001 Dec; 98(13):3527-33. PubMed ID: 11739153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.
    Huang L; Xu J; Wood DJ; Zheng MH
    Am J Pathol; 2000 Mar; 156(3):761-7. PubMed ID: 10702390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
    Grimaud E; Soubigou L; Couillaud S; Coipeau P; Moreau A; Passuti N; Gouin F; Redini F; Heymann D
    Am J Pathol; 2003 Nov; 163(5):2021-31. PubMed ID: 14578201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM; Croucher PI
    Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages.
    Itonaga I; Sabokbar A; Murray DW; Athanasou NA
    Ann Rheum Dis; 2000 Jan; 59(1):26-31. PubMed ID: 10627423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.
    Kostenuik PJ; Shalhoub V
    Curr Pharm Des; 2001 May; 7(8):613-35. PubMed ID: 11375772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
    Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
    Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture.
    Komine M; Kukita A; Kukita T; Ogata Y; Hotokebuchi T; Kohashi O
    Bone; 2001 May; 28(5):474-83. PubMed ID: 11344046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.
    Giuliani N; Colla S; Sala R; Moroni M; Lazzaretti M; La Monica S; Bonomini S; Hojden M; Sammarelli G; Barillè S; Bataille R; Rizzoli V
    Blood; 2002 Dec; 100(13):4615-21. PubMed ID: 12393684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated.
    Gori F; Hofbauer LC; Dunstan CR; Spelsberg TC; Khosla S; Riggs BL
    Endocrinology; 2000 Dec; 141(12):4768-76. PubMed ID: 11108292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
    Shalhoub V; Faust J; Boyle WJ; Dunstan CR; Kelley M; Kaufman S; Scully S; Van G; Lacey DL
    J Cell Biochem; 1999 Feb; 72(2):251-61. PubMed ID: 10022507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene.
    Cheung J; Mak YT; Papaioannou S; Evans BA; Fogelman I; Hampson G
    J Endocrinol; 2003 Jun; 177(3):423-33. PubMed ID: 12773123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T; Utsuyama M; Hirokawa K
    J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effects of 17 beta-estradiol on the expression of osteoprotegerin, the ligand of osteoprotegerin and related cytokines in osteosarcoma MG63 cells].
    Su X; Liao EY; Peng J; Wu XP
    Zhonghua Nei Ke Za Zhi; 2003 Nov; 42(11):800-3. PubMed ID: 14636471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
    Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
    Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoprotegerin and osteoprotegerin ligand expression during human marrow stromal cell differentiation and their effect on osteoclast formation.
    Yang L; Hai Y; Zhou JL
    Chin Med J (Engl); 2011 Jul; 124(13):2033-7. PubMed ID: 22088466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
    Burgess TL; Qian Y; Kaufman S; Ring BD; Van G; Capparelli C; Kelley M; Hsu H; Boyle WJ; Dunstan CR; Hu S; Lacey DL
    J Cell Biol; 1999 May; 145(3):527-38. PubMed ID: 10225954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANK ligand and osteoprotegerin in myeloma bone disease.
    Sezer O; Heider U; Zavrski I; Kühne CA; Hofbauer LC
    Blood; 2003 Mar; 101(6):2094-8. PubMed ID: 12424190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
    Lee SK; Lorenzo JA
    Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.